AstraZeneca PLC (AZN)vsBiora Therapeutics Inc (BIOR)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
BIOR
Biora Therapeutics Inc
$0.22
0.00%
HEALTHCARE · Cap: $994,990
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6830016% more annual revenue ($58.74B vs $860,000). AZN leads profitability with a 17.4% profit margin vs 0.0%. BIOR trades at a lower P/E of 0.6x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BIOR
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+73.2%
Fair Value
$0.82
Current Price
$0.22
$0.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Revenue surging 15800.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : BIOR
The strongest argument for BIOR centers on P/E Ratio, Revenue Growth. Revenue growth of 15800.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BIOR
The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while BIOR is a hypergrowth play — different risk/reward profiles.
BIOR carries more volatility with a beta of 1.28 — expect wider price swings.
BIOR is growing revenue faster at 15800.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 38/100), backed by strong 17.4% margins. BIOR offers better value entry with a 73.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Biora Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?